Release Date: March 15, 2024
Expiration Date: March 15, 2025

Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

While newer-generation Janus kinase (JAK) inhibitors have improved outcomes in patients with myelofibrosis (MF), nevertheless, treatment for MF is still limited by treatment failure, dose-limiting cytopenias and nonhematologic toxicities. At the 2023 American Society of Hematology (ASH) Annual Meeting, a series of clinical trials reported results of emerging MF therapies that have the potential to support improved outcomes in patients with MF, as each is approved. Highlights of trials include data reported from the PERSIST-2 and PAC203 trials of pacritinib and the SIMPLIFY-1 and MOMENTUM trials of momelotinib, findings of the TRANSFORM-1 trial of navitoclax, and more.

Target Audience

This activity is designed for the multidisciplinary team of community-based hematology/oncology physicians and community-based advanced practice providers who provide care to patients with MF.

Learning Objective

Upon completion of this educational activity, participants should be able to:

• Summarize new advances and emerging safety and efficacy data for new and recently approved JAK inhibitors as presented at the 2023 ASH Annual Meeting
• Outline interim clinical trial results focusing on safety and efficacy data of non-JAK inhibitors with novel mechanisms in patients with MF

Agenda

New Advances in JAK Inhibitors and non-JAK Inhibitors in Myelofibrosis: Updates from ASH 2023

• PERSIST-2 and PAC203
• SIMPLIFY-1 and MOMENTUM
• MANIFEST-2
• TRANSFORM-1
• FREEDOM2
• XPORT-MF-034

Instructions for Participation and Credit

This activity is eligible for credit through March 15, 2025. After this date, this activity will expire and no further credit will be awarded.

1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME and CE may be printed immediately after successfully completing the post-test and activity evaluation.

Accreditation

	CME CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MediCom Worldwide, Inc. designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Medical Writer Disclosure

Lillian McVey, medical writer for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.

Planning Committee

Joan Meyer, RN, MHA, Executive Director; Sheri Sturgis, Strategy and Education Manager; and Jennifer Murphy, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Karyopharm Therapeutics.

©2024 MediCom Worldwide, Inc., 4607 Library Rd., Ste. 220 #2001 · Bethel Park, PA 15102, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.